Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 238Gynecologic 7Tumor-Agnostic 4Genitourinary 4Thoracic 3Other 2Gastrointestinal 2Endocrine 2Other neoplasm 1NET 1Lymphoid 1Head & Neck 1

Conditions

Hormone Receptor Positive Malignant Neoplasm of Breast 1

Interventions

Cyclophosphamide 13Peripheral Blood Stem Cell Transplantation 9Biopsy 9fludarabine phosphate 8Busulfan 8Whole-Body Irradiation 7Surveys and Questionnaires 6Mycophenolic Acid 6Educational Status 6Early Intervention, Educational 6Carboplatin 6fludarabine 5Tacrolimus 5Paclitaxel 5Methotrexate 5Methods 5Melphalan 5Epoetin Alfa 5Decitabine 5Cyclosporine 5Colposcopy 5Cisplatin 5Celecoxib 5Antilymphocyte Serum 5Aminolevulinic Acid 5Sulindac 4Selenium 4Radiotherapy 4Patient Reported Outcome Measures 4Magnetic Resonance Spectroscopy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × exemestane × Other neoplasm × Clear all
NCT02025712 2014-01-01

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Organisation for Oncology and Translational Research

Phase 2 Unknown
35 enrolled
BreastOther neoplasm

Hormone Receptor Positive Malignant Neoplasm of Breast

Data powered by HemOnc (CC BY 4.0) Colophon âš¡